Two new treatment options for infections due to drug-resistant gram-positive cocci
1Department of Infectious Diseases, The Cleveland Clinic Foundation, OH 44195, USA. rehms@ccf.org
Abstract:
Gram-positive cocci, including enterococci and Staphylococcus aureus, have become the leading cause of hospital-acquired infections, and their resistance to antibiotics is increasing. Two important new drugs-quinupristin/dalfopristin (Synercid) and linezolid (Zyvox)-were designed specifically to treat infections due to drug-resistant gram-positive cocci. But their use must be tempered by their cost, toxicity, and concerns about further development of resistant strains.
More Related Videos
Related Concept Videos
Antibiotic Selection
Acute Pyelonephritis II: Diagnostic Studies and Management
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance


